ATI-106

ATI-106 is an investigational, preclinical-stage drug candidate being developed by Adjuvia Therapeutics for the treatment of Alzheimer's disease and other neurodegenerative disorders. The compound is part of Adjuvia's pipeline focusing on mitochondrial-targeted therapies. While the specific active pharmaceutical ingredient and molecular target for ATI-106 have not been explicitly disclosed, the company utilizes a proprietary nanoparticle delivery platform designed to enhance the delivery of therapeutic agents to the mitochondria and across the blood-brain barrier. This approach aims to combat oxidative stress and mitochondrial dysfunction, which are key drivers in the progression of neurodegenerative diseases.